Brooke McCormick

Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.

Zidesamtinib offers a new treatment option for previously treated ROS1-positive NSCLC, with rapid, durable responses and strong brain activity.

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

In part 2, Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how earlier referrals, AI, and less prior authorization can improve cancer outcomes.

A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.

A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Grace Mackleby, PhD, explores why dually eligible beneficiaries more often switch MA plans than leave for traditional Medicare.

The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.

A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.

Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.

In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access.

In part 2, Rosa Novo discusses how employers can expand access to cancer screening and why they need a greater voice in shaping cancer care.

Amanda Green, MPH, discusses how employers can improve benefit awareness, care navigation, cancer prevention, and cost strategies.

Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community oncology.

Advanced primary care, return-to-work support, and survivorship follow-up are key employer cancer strategies, said Karen van Caulil, PhD.

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, and ensure accountability.

The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.

Karen van Caulil, PhD, explained why employers evaluating cancer care weigh timely access, quality, and equity alongside cost.

Stephen "Fred" Divers, MD, discusses how COA study data push back on payer bias and support community oncology's long-term sustainability.

David Johnson, MD, MPH, discusses how payer data can reduce low-value cancer care and steer patients to supportive services and cost-efficient sites.

Stephen “Fred” Divers, MD, discusses findings showing community oncology delivers outcomes comparable with academic care for breast cancer and NSCLC.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.

Christine Pfaff, RPh, MBA, discusses barriers to community cellular therapy delivery and the need for new business models and payer collaboration.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.